This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
by Zacks Equity Research
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
ALLOPositive Net Change RGENPositive Net Change ANIKNegative Net Change
biotechs earnings medical
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
by Zacks Equity Research
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
LQDAPositive Net Change UTHRPositive Net Change RGENPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
by Ahan Chakraborty
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Undervalued Price-to-Book Stocks Worth Buying in August
by Kinjel Shah
BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
BMRNNegative Net Change IVZPositive Net Change ROCKNegative Net Change CNCNegative Net Change HPENegative Net Change
biotechs construction finance medical pharmaceuticals
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
by Ekta Bagri
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
BMYPositive Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
by Kanishka Das
Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
AMRXPositive Net Change TEVANegative Net Change NBIXPositive Net Change
biotechs
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
by Zacks Equity Research
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
ALKSPositive Net Change RGENPositive Net Change LQDAPositive Net Change
biotechs
Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces near-term pressure from flat Wegovy sales, pricing challenges and pipeline setbacks, but its broad cardiometabolic pipeline offers long-term potential.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
TNGX Stock Dips 5% as Q2 Earnings Miss Estimates on Higher Expenses
by Zacks Equity Research
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
TNGXNegative Net Change RGENPositive Net Change AMRNNegative Net Change LQDAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
by Zacks Equity Research
RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
RCKTNegative Net Change RGENPositive Net Change LQDAPositive Net Change
biotechs earnings